bioRxiv · 10.1101/2022.05.06.490907
GDF15 and ACE2 stratify COVID19 patients according to severity while ACE2 mutations increase infection susceptibility.
Abstract
Coronavirus disease 19 (COVID-19) is a persistent global pandemic with a very heterogeneous disease presentation ranging from a mild disease to dismal prognosis. Early detection of sensitivity and severity of COVID-19 is essential for the development of new treatments. In the present study, we measured the levels of circulating growth differentiation factor 15 (GDF15) and angiotensin-converting enzyme 2 (ACE2) in plasma of severity-stratified COVID-19 patients and healthy control patients and characterized the in vitro effects and cohort frequency of ACE2 SNPs. Our results show that while circulating GDF15 and ACE2 stratify COVID-19 patients according to disease severity, ACE2 missense SNPs constitute a risk factor linked to infection susceptibility.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Torrens-Mas, M., Perello-Reus, C. M., Trias-Ferrer, N., Ibarguen-Gonzalez, L., Crespi, C., Galmes-Panades, A. M., Navas-Enamorado, C., Sanchez-Polo, A., Pierola-Lopetegui, J., Masmiquel, L., Socias Crespi, L., Barcelo, C., Gonzalez-Freire, M.. 2022-05-06. GDF15 and ACE2 stratify COVID19 patients according to severity while ACE2 mutations increase infection susceptibility.. https://doi.org/10.1101/2022.05.06.490907
Cite the original work for its findings. Save a collection to share your selection of sources.